Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.60 |
| ▸ | CDK2 | P24941 | 14/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.49 |
| ▸ | GPR39 | O43194 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953665 | 0.92 | GSK3B (0.63) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13305409 | 0.89 | GSK3B (0.58) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12953524 | 0.89 | GSK3B (0.77) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13304910 | 0.89 | GSK3B (0.60) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13305401 | 0.88 | GSK3B (0.56) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13305326 | 0.88 | GSK3B (0.56) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL14043290 | 0.87 | GSK3B (0.60) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL14050761 | 0.87 | GSK3B (0.55) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12953517 | 0.86 | GSK3B (0.54) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13305706 | 0.85 | GSK3B (0.54) | GSK3BCDK2CCNA2CCNA1GPR39 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008130569-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |